It is really a dose deescalation for FTO. We know the MTD, but we don’t know what is the minimum amount of Zantrene we need to use to fully inhibit FTO in people. You can’t just pick a number out of the air and go with that if you want the FDA to approve your Phase 3 trials.
Pillar 3 - AML, page-117
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.085(4.90%) |
Mkt cap ! $284.4M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.65 | $22.26K | 13.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2897 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 115 | 1 |
View Market Depth
| Last trade - 11.02am 24/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |